v3.25.2
Investments
6 Months Ended
Jun. 30, 2025
Investments [Abstract]  
Investments We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. As a
REIT, we generally limit our ownership of each individual entity’s voting stock to less than 10%. We evaluate each investment to
determine whether we have the ability to exercise significant influence, but not control, over an investee. We evaluate investments in
which our ownership is equal to or greater than 20%, but less than or equal to 50%, of an investee’s voting stock with a presumption
that we have this ability. For our investments in limited partnerships that maintain specific ownership accounts, we presume that such
ability exists when our ownership interest exceeds 3% to 5%. In addition to our ownership interest, we consider whether we have a
board seat or whether we participate in the investee’s policy-making process, among other criteria, to determine if we have the ability to
exert significant influence, but not control, over an investee. If we determine that we have such ability, we account for the investment
under the equity method, as described below.
From time to time, we may hold equity investments in publicly traded companies that are subject to temporary contractual sale
restrictions. We do not recognize a discount related to such contractual sale restrictions.
Investments accounted for under the equity method
Under the equity method of accounting, we initially recognize our investment at cost and subsequently adjust the carrying
amount of the investment for our share of earnings or losses reported by the investee, distributions received, and other-than-temporary
impairments.
As of June 30, 2025, we had ten investments in limited partnerships maintaining specific ownership accounts for each investor,
which were accounted for under the equity method. These investments aggregated $276.8 million. Our ownership interest in each of
these ten investments was greater than 5%.
Investments that do not qualify for the equity method of accounting
For investees over which we determine that we do not have the ability to exercise significant influence or control, we account
for each investment depending on whether it is an investment in a (i) publicly traded company, (ii) privately held entity that reports NAV
per share, or (iii) privately held entity that does not report NAV per share, as described below.
Investments in publicly traded companies
Our investments in publicly traded companies are classified as investments with readily determinable fair values and are
presented at fair value in our consolidated balance sheets, with changes in fair value classified in investment income (loss) in our
consolidated statements of operations. The fair values for our investments in publicly traded companies are determined based on sales
prices or quotes available on securities exchanges.
Investments in privately held companies
Our investments in privately held entities without readily determinable fair values consist of (i) investments in privately held
entities that report NAV per share and (ii) investments in privately held entities that do not report NAV per share. These investments are
accounted for as follows:
Investments in privately held entities that report NAV per share
Investments in privately held entities that report NAV per share, such as our privately held investments in limited partnerships,
are presented at fair value using NAV as a practical expedient, with changes in fair value classified in investment income (loss) in our
consolidated statements of operations. We use NAV per share reported by limited partnerships generally without adjustment, unless we
are aware of information indicating that the NAV reported by a limited partnership does not accurately reflect the fair value of the
investment at our reporting date.
Investments in privately held entities that do not report NAV per share
Investments in privately held entities that do not report NAV per share are accounted for using a measurement alternative
under which these investments are measured at cost, adjusted for observable price changes and impairments, with changes classified
in investment income (loss) in our consolidated statements of operations.
An observable price arises from an orderly transaction for an identical or similar investment of the same issuer, which is
observed by an investor without expending undue cost and effort. Observable price changes result from, among other things, equity
transactions of the same issuer executed during the reporting period, including subsequent equity offerings or other reported equity
transactions related to the same issuer. To determine whether these transactions are indicative of an observable price change, we
evaluate, among other factors, whether these transactions have similar rights and obligations, including voting rights, distribution
preferences, and conversion rights to the investments we hold.
Impairment evaluation of equity method investments and investments in privately held entities that do not report NAV per share
We monitor equity method investments and investments in privately held entities that do not report NAV per share for new
developments, including operating results, prospects and results of clinical trials, new product initiatives, new collaborative agreements,
capital-raising events, and merger and acquisition activities. These investments are evaluated on the basis of a qualitative assessment
for indicators of impairment by monitoring the presence of the following triggering events or impairment indicators:
(i)a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee;
(ii)a significant adverse change in the regulatory, economic, or technological environment of the investee;
(iii)a significant adverse change in the general market condition, including the research and development of technology and
products that the investee is bringing or attempting to bring to the market;
(iv)significant concerns about the investee’s ability to continue as a going concern; and/or
(v)a decision by investors to cease providing support or reduce their financial commitment to the investee.
If such indicators are present, we are required to estimate the investment’s fair value and immediately recognize an
impairment charge in an amount equal to the investment’s carrying value in excess of its estimated fair value.
Investment income/loss recognition and classification
We recognize both realized and unrealized gains and losses in our consolidated statements of operations, classified in
investment income (loss) in our consolidated statements of operations. Unrealized gains and losses represent:
(i)changes in fair value for investments in publicly traded companies;
(ii)changes in NAV for investments in privately held entities that report NAV per share;
(iii)observable price changes for investments in privately held entities that do not report NAV per share; and
(iv)our share of unrealized gains or losses reported by our equity method investees.
Realized gains and losses on our investments represent the difference between proceeds received upon disposition of
investments and their historical or adjusted cost basis. For our equity method investments, realized gains and losses represent our
share of realized gains or losses reported by the investee. Impairments are realized losses, which result in an adjusted cost basis, and
represent charges to reduce the carrying values of investments in privately held entities that do not report NAV per share and equity
method investments, if impairments are deemed other than temporary, to their estimated fair value.
Funding commitments to investments in privately held entities that report NAV
We are committed to funding approximately $351.0 million for our investments in privately held entities that report NAV. Our
funding commitments expire at various dates over the next 12 years, with a weighted-average expiration of 8.0 years as of June 30,
2025. These investments are not redeemable by us, but we may receive distributions from these investments throughout their terms.
Our investments in privately held entities that report NAV generally have expected initial terms in excess of 10 years. The weighted-
average remaining term during which these investments are expected to be liquidated was 5.2 years as of June 30, 2025.
The following tables summarize our investments as of June 30, 2025 and December 31, 2024 (in thousands):
June 30, 2025
Cost
Unrealized
Gains
Unrealized
Losses
Carrying
Amount
Publicly traded companies
$183,859
$18,365
$(120,299)
$81,925
Entities that report NAV
497,975
97,201
(43,013)
552,163
Entities that do not report NAV:
Entities with observable price changes
78,105
64,585
(9,156)
133,534
Entities without observable price changes
432,299
432,299
Investments accounted for under the equity method
N/A
N/A
N/A
276,775
Total investments
$1,192,238
$180,151
$(172,468)
$1,476,696
December 31, 2024
Cost
Unrealized
Gains
Unrealized
Losses
Carrying
Amount
Publicly traded companies
$188,653
$24,262
$(107,248)
$105,667
Entities that report NAV
518,074
126,077
(34,285)
609,866
Entities that do not report NAV:
Entities with observable price changes
99,932
77,761
(2,956)
174,737
Entities without observable price changes
400,487
400,487
Investments accounted for under the equity method
N/A
N/A
N/A
186,228
Total investments
$1,207,146
$228,100
$(144,489)
$1,476,985
Cumulative gains and losses (realized and unrealized) on investments in privately held entities that do not report NAV still held
as of June 30, 2025 aggregated to a loss of $123.3 million, which consisted of upward adjustments aggregating $64.6 million,
downward adjustments aggregating $9.2 million, and impairments aggregating $178.7 million.
Our investment income (loss) for the three and six months ended June 30, 2025 and 2024 consisted of the following (in
thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Realized (losses) gains
$(8,684)
(1)
$20,578
$9,469
(1)
$34,704
Unrealized losses
(21,938)
(64,238)
(90,083)
(35,080)
Investment loss
$(30,622)
$(43,660)
$(80,614)
$(376)
(1)Consists of realized gains of $30.5 million and $59.9 million, partially offset by impairment charges of $39.2 million and $50.4 million during the three and six months
ended June 30, 2025, respectively.
During the six months ended June 30, 2025, gains and losses on investments in privately held entities that do not report NAV
still held as of June 30, 2025 aggregated to a loss of $57.6 million, which consisted of upward adjustments aggregating $8.8 million and
downward adjustments and impairments aggregating $66.4 million.
During the six months ended June 30, 2024, gains and losses on investments in privately held entities that do not report NAV
still held as of June 30, 2024 aggregated to a loss of $13.7 million, which consisted of upward adjustments aggregating $15.7 million
and downward adjustments and impairments aggregating $29.4 million.
Unrealized gains or losses related to investments still held (excluding investments accounted for under the equity method) as
of June 30, 2025 and 2024 aggregated to a loss of $30.7 million and a loss of $1.8 million during the six months ended June 30, 2025
and 2024, respectively.
Our investment loss of $80.6 million for the six months ended June 30, 2025 also included $102 thousand of equity in losses of
our equity method investments.
Refer to “Investments” in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated financial
statements for additional information